BCM
KYNB

Bridgeway Capital Management’s Kyntra Bio KYNB Stock Holding History

Bridgeway Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,260
Closed -$62.5K – 1236
2024
Q3 		$62.5K Sell
6,260
-200
-3% -$3.02K ﹤0.01% 1201
2024
Q2 		$144K Sell
6,460
-2,260
-26% -$69.8K ﹤0.01% 1117
2024
Q1 		$512K Buy
+8,720
New +$376K 0.01% 917

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bridgeway Capital Management's KYNB Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Kyntra Bio (KYNB) in Q4 2024, closing a stake of 6,260 shares — an estimated $62.5K sold.

Bridgeway Capital Management first reported a position in KYNB in Q1 2024 and held it in 3 quarters. The position peaked at $512K in Q1 2024. 68 funds tracked by Wall St. Rank hold KYNB as of Q4 2024.

  • Bridgeway Capital Management reported no remaining Kyntra Bio position as of Q4 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 6,260 Kyntra Bio shares in Q4 2024, an estimated $62.5K.
  • Bridgeway Capital Management first reported a position in Kyntra Bio in Q1 2024 and held it in 3 quarters.
  • Bridgeway Capital Management's Kyntra Bio position peaked at $512K in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.